Table 2.
Baseline and 6-week SGRQ results for the two groups.
| ETG Pre | ETG Post | p * | CG Pre | CG Post | p * | Between Group Δ Post-Pre p † | Effect Size | |
|---|---|---|---|---|---|---|---|---|
| SYMPTOMS | 48.18 [27.86–60.65] |
37.53 [27.44–55.49] |
<0.27 | 38.52 [6.65–55.64] |
28.36 [9.94–56.06] |
<0.75 | 0.66 | −0.31 |
| ACTIVITY | 32.33 [11.21–53.53] |
38.30 [17.12–53.49] |
<0.82 | 23.63 [11.87–41.42] |
29.93 [20.33–50.40] |
<0.73 | 0.74 | −0.115 |
| IMPACT OF LIFE | 20.03 [8.21–41.00] |
17.43 [10.93–21.22] |
<0.39 | 20.56 [9.92–25.65] |
17.25 [11.42–21.76] |
<0.61 | 0.30 | −0.43 |
| GLOBAL | 24.61 [14.91–49.19] |
25.54 [17.15–31.36] |
<0.35 | 26.08 [11.22–35.85] |
24.80 [10.45–30.41] |
<0.50 | 0.50 | −0.171 |
*—within-group analysis (Wilcoxon signed-rank test); †—between-group analysis (Mann-Whitney U test).